// App-Quantinova.ai

THU0120 : LONG-TERM SAFETY OF RITUXIMAB: 10-YEAR FOLLOW-UP IN THE RHEUMATOID ARTHRITIS GLOBAL CLINICAL TRIAL PROGRAMME

Researchers

Presenter

  • R.F. van Vollenhoven

Principal Investigators

  • P. Emery

  • C.O. Bingham

  • E. Keystone

  • R. Fleischmann

  • D.E. Furst

  • N. Tyson

  • A. Mehbob

  • P.B. Lehane

Medical Centers

  • Leeds General Infirmary, Leeds, United Kingdom

  • UCLA, Los Angeles, California, United States

  • Karolinska Institutet, Stockholm, Sweden

  • John Hopkins University, Baltimore, Maryland, United States

Locations

  • United States

  • Canada

  • United Kingdom

  • Sweden

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Cardiorenal syndrome

  • Myocardial infarction

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Methotrexate

  • Rituximab

  • Citalopram

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved